Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Textiles Press Releases.
Press releases published on May 8, 2025

Ligand Reports First Quarter 2025 Financial Results
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $ …

Entrada Therapeutics Reports First Quarter 2025 Financial Results
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 …

Verano Announces First Quarter 2025 Financial Results
CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) ("Verano" or the "Company"), a leading multi-state cannabis company, today announced its financial results for the first quarter ended March 31, 2025, which were …

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, …

ProQR Announces First Quarter 2025 Operating and Financial Results
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer …

Kaltura Announces Financial Results for First Quarter 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Kaltura, Inc. (“Kaltura” or the “Company”), the video experience cloud, today announced financial results for the first quarter ended March 31, 2025, as well as outlook for the second quarter and full year 2025. " …

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference
HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …

Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
VAV1-directed MRT-6160 program advancing toward multiple Phase 2 studies, enabled by Phase 1 SAD/MAD study data supporting broad potential application in immune-mediated diseases MRT-2359 Phase 1/2 study data demonstrate encouraging signals of clinical …

BigCommerce Announces First Quarter 2025 Financial Results
AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- BigCommerce Holdings, Inc. (“BigCommerce” or the “Company”) (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands, retailers, manufacturers and …

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in …

Microbix Schedules Release of Results for Q2 Fiscal 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure …

Zoomcar Announces Trading on OTCQX Best Market
Bangalore, India, May 08, 2025 (GLOBE NEWSWIRE) -- Zoomcar Holdings, Inc. (“Zoomcar” or the “Company”) (OTCQX: ZCAR), a leading marketplace for self-drive car sharing in India, announced that its common shares and warrants are transitioning from the Nasdaq …

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership …

Syndax Announces Participation in May Investor Conferences
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as …

Aptose Reports First Quarter 2025 Results
SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat …

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, …

Liquidity Services Announces Second Quarter Fiscal Year 2025 Financial Results
BETHESDA, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidity Services (NASDAQ:LQDT; www.liquidityservices.com), a leading global commerce company powering the circular economy, today announced its financial results for its fiscal quarter ended March 31, 2025, …

MAG Silver Reports First Quarter Financial Results
VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, or the “Company”) announces the Company’s unaudited consolidated financial results for the three months ended March 31, 2025 (“Q1 2025”). For …

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced …

Blue Moon Metals Announces Start of Mobilization for Nussir Underground Development, Follow on Equity Investment of C$1.13M From Mining Contractor and Engagement of Market Maker
TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON; OTCQX: BMOOF), is pleased to announce the mobilization of Leonhard Nilsen …